

	Particulars	Standalone					Consolidated	
		Quarter ended			Year ended		Year ended	
		31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015	31.03.2016	31.03.2015
		(Unaudited)			(Audited)		(Audited)	
1	Income from operations							
a	Net sales / income from operations (net of excise duty)	10,512.44	9,058.71	9,633.24	38,972.08	36,730.33	40,749.96	38,396.20
b	Other operating income	163.67	136.46	157.04	475.76	638.50	475.76	638.50
	Total income from operations (net)	10,676.11	9,195.17	9,790.28	39,447.84	37,368.83	41,225.72	39,034.70
2	Expenses							
a	Cost of materials consumed	3,210.22	3,045.00	3,314.99	13,177.29	13,127.13	14,091.66	14,002.88
b	Purchases of stock-in-trade	154.23	210.07	107.42	676.13	652.53	676.13	652.53
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	265.72	(156.07)	284.91	200.25	(306.83)	21.03	(397.94)
d	Employee benefits expense	1,853.94	1,758.29	1,478.94	6,899.23	6,030.00	7,477.49	6,499.18
e	Depreciation and amortisation expense	509.11	497.19	482.48	2,018.80	1,808.99	2,102.89	1,877.09
f	Other expenses	2,577.25	2,376.39	2,672.65	10,048.79	9,602.68	10,381.81	9,865.77
	Total expenses	8,570.47	7,730.87	8,341.39	33,020.49	30,914.50	34,751.01	32,499.51
3	Profit from operations before other income, finance costs and exceptional items (1-2)	2,105.64	1,464.30	1,448.89	6,427.35	6,454.33	6,474.71	6,535.19
4	Other income	194.26	173.99	123.41	838.50	822.14	826.59	812.05
5	Profit from ordinary activities before finance costs and exceptional items (3 + 4)	2,299.90	1,638.29	1,572.30	7,265.85	7,276.47	7,301.30	7,347.24
6	Finance costs	205.45	220.04	174.13	778.24	822.65	797.14	829.85
7	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	2,094.45	1,418.25	1,398.17	6,487.61	6,453.82	6,504.16	6,517.39
8	Exceptional items	-	-	-	-	1,957.80	-	1,957.80
9	Profit from ordinary activities before tax (7 + 8)	2,094.45	1,418.25	1,398.17	6,487.61	8,411.62	6,504.16	8,475.19
10	Tax expense	653.89	364.66	187.80	1,756.87	2,309.90	1,756.87	2,309.90
11	Net Profit from ordinary activities after tax (9 - 10)	1,440.56	1,053.59	1,210.37	4,730.74	6,101.72	4,747.29	6,165.29
12	Extraordinary items	-	-	-	-	-	-	-
13	Net Profit for the period (11 + 12)	1,440.56	1,053.59	1,210.37	4,730.74	6,101.72	4,747.29	6,165.29
14	Share of profit / (loss) of associates						79.50	66.99
15	Loss attributable to Minority interest						-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	1,440.56	1,053.59	1,210.37	4,730.74	6,101.72	4,826.79	6,232.28
17	Paid-up equity share capital (Face Value of ₹ 5 each)	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				20,177.89	16,991.29	20,657.47	17,412.03
19	Earnings per share (before extraordinary items) (Quarterly not annualised and yearly annualised) :							
	Basic / Diluted (₹)	3.27	2.39	2.75	10.72	13.83	10.94	14.12



Statement of Assets and Liabilities					
Particulars	Standalone		Consolidated		
	As at		As at		
	31.03.2016	31.03.2015	31.03.2016	31.03.2015	
	Audited	Audited	Audited	Audited	
A EQUITY AND LIABILITIES					
1 Shareholders' funds					
(a) Share capital	2,205.67	2,205.67	2,205.67	2,205.67	
(b) Reserves and surplus	20,177.89	16,991.29	20,657.47	17,412.03	
Sub-total - Shareholders' funds	22,383.56	19,196.96	22,863.14	19,617.70	
2 Minority interest	-	-	(0.26)	(0.25)	
3 Non-current liabilities					
(a) Long-term borrowings	3,106.28	4,024.56	3,106.28	4,024.56	
(b) Deferred tax liabilities (net)	1,183.37	1,028.48	1,183.37	1,028.48	
(c) Other long-term liabilities	357.99	265.56	357.99	265.56	
(d) Long-term provisions	256.51	203.83	256.51	203.83	
Sub-total - Non-current liabilities	4,904.15	5,522.43	4,904.15	5,522.43	
4 Current liabilities					
(a) Short-term borrowings	3,039.38	1,807.37	3,345.59	2,105.02	
(b) Trade payables	2,957.53	3,803.69	3,087.15	3,932.88	
(c) Other current liabilities	3,797.33	3,756.89	3,988.98	3,865.63	
(d) Short-term provisions	503.08	1,358.33	503.08	1,358.33	
Sub-total - Current liabilities	10,297.32	10,726.28	10,924.80	11,261.86	
TOTAL - EQUITY AND LIABILITIES	37,585.03	35,445.67	38,691.83	36,401.74	
B ASSETS					
1 Non-current assets					
(a) Fixed assets	19,096.77	17,046.39	19,606.52	17,527.26	
(b) Non-current investments	561.06	561.06	442.21	395.48	
(c) Long-term loans and advances	1,290.91	2,373.38	1,290.91	2,204.64	
(d) Other non-current assets	336.47	334.72	336.47	324.04	
Sub-total - Non-current assets	21,285.21	20,315.55	21,676.11	20,451.42	
2 Current assets					
(a) Inventories	4,058.25	5,387.30	4,600.04	5,762.24	
(b) Trade receivables	8,029.07	5,949.14	8,253.76	6,280.73	
(c) Cash and cash equivalents	2,147.87	1,983.38	2,172.55	1,998.30	
(d) Short-term loans and advances	1,283.06	1,054.89	1,226.84	1,150.83	
(e) Other current assets	781.57	755.41	762.53	758.22	
Sub-total - Current assets	16,299.82	15,130.12	17,015.72	15,950.32	
TOTAL - ASSETS	37,585.03	35,445.67	38,691.83	36,401.74	

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 13th May 2016.
- The Board of Directors have recommended a final dividend of Rs 0.50 per equity share of Rs 5 each subject to approval of shareholders. This is in addition to interim dividend of Rs 2.50 per equity share of Rs 5 each declared and paid in the month of March 2016, thus making it to Rs 3 per equity share of Rs 5 each.
- The figures of last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended 31st March and the unaudited published year-to-date figures upto the third quarter ended 31st December.
- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- In view of option allowed by the Ministry of Corporate Affairs vide its notification dated 29th December 2011 on AS 11, the exchange differences arising on reporting of long term foreign currency monetary items at rates different from those at which they were initially recorded have been accumulated in a "Foreign Currency Monetary Items Translation Difference Account" to be amortised over the balance period of such long term assets or liabilities. Pursuant to such adoption, a sum of ₹ 3.69 lacs is remained to be amortised over the balance period of such assets or liabilities.
- The consolidated Financial Statement has been prepared in accordance with AS- 21 " Consolidated Financial Statements" and AS-23 " Accounting for investment in Associates in Consolidated financial Statements".
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

Place : New Delhi
Date : 13.05.2016



By order of the Board


Himanshu Baid
Managing Director

BSE SCRIP CODE : 531768

NSE SCRIP CODE : POLYMED

FORM A (for audit report with unmodified opinion)

(Pursuant to regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

1.	Name of the Company	Poly Medicure Limited
2.	Annual financial statements for the year ended	31 st March, 2016
3.	Types of Audit observation	Un-Modified
4.	Frequency of observation	Not Applicable
5.	Signed by- For Poly Medicure Ltd.  Himanshu Baid Managing Director Himanshu Baid Managing Director For POLY MEDICURE LTD.  Vice President (Finance) & CFO J. K. Oswal Chief Financial Officer  Prakash Chand Surana Audit Committee Chairman Place of Signature: New Delhi Date : 13th May, 2016	Signed by- Auditors For Doogar & Associates Chartered Accountants  M. S. Agarwal Partner M. No. 86580 FRN. 000561N  Place of Signature: New Delhi Date: 13th May, 2016